CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
100.70
0.59%
Market Trading Hours* (UTC) Open now
Closes on Friday at 21:00

Mon - Thu: 08:10 - 00:00

Fri: 08:10 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.21
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Moderna Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 101.3
Open* 101.75
1-Year Change* -28.11%
Day's Range* 99.92 - 101.75
52 wk Range 62.55-198.86
Average Volume (10 days) 5.29M
Average Volume (3 months) 106.64M
Market Cap 37.77B
P/E Ratio -100.00K
Shares Outstanding 381.28M
Revenue 9.12B
EPS -9.36
Dividend (Yield %) N/A
Beta 1.69
Next Earnings Date Feb 22, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 18, 2024 101.00 -2.37 -2.29% 103.37 103.64 99.85
Apr 17, 2024 103.05 0.16 0.16% 102.89 105.47 102.20
Apr 16, 2024 103.45 0.50 0.49% 102.95 106.33 101.34
Apr 15, 2024 103.39 -1.06 -1.01% 104.45 106.11 102.20
Apr 12, 2024 104.86 -1.84 -1.72% 106.70 107.76 104.46
Apr 11, 2024 106.10 -0.59 -0.55% 106.69 108.37 103.64
Apr 10, 2024 106.90 -4.71 -4.22% 111.61 112.53 105.85
Apr 9, 2024 111.95 7.72 7.41% 104.23 115.80 103.95
Apr 8, 2024 104.65 2.20 2.15% 102.45 105.16 100.96
Apr 5, 2024 102.52 0.77 0.76% 101.75 103.73 101.01
Apr 4, 2024 101.55 0.28 0.28% 101.27 105.91 100.96
Apr 3, 2024 100.96 -2.69 -2.60% 103.65 104.95 96.95
Apr 2, 2024 103.41 -2.27 -2.15% 105.68 106.40 102.96
Apr 1, 2024 105.00 -1.97 -1.84% 106.97 108.37 103.50
Mar 28, 2024 106.57 -3.48 -3.16% 110.05 111.82 105.95
Mar 27, 2024 109.97 2.26 2.10% 107.71 112.93 104.97
Mar 26, 2024 107.36 -2.99 -2.71% 110.35 111.86 106.88
Mar 25, 2024 110.20 4.80 4.55% 105.40 110.79 105.08
Mar 22, 2024 105.15 0.86 0.82% 104.29 105.91 103.28
Mar 21, 2024 104.04 1.09 1.06% 102.95 106.26 102.50

Moderna Inc Events

Time (UTC) Country Event
Thursday, May 2, 2024

Time (UTC)

12:00

Country

US

Event

Moderna Inc Annual Shareholders Meeting
Moderna Inc Annual Shareholders Meeting

Forecast

-

Previous

-

Time (UTC)

12:30

Country

US

Event

Q1 2024 Moderna Inc Earnings Release
Q1 2024 Moderna Inc Earnings Release

Forecast

-

Previous

-
Monday, May 6, 2024

Time (UTC)

12:00

Country

US

Event

Moderna Inc Annual Shareholders Meeting
Moderna Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Thursday, August 1, 2024

Time (UTC)

12:30

Country

US

Event

Q2 2024 Moderna Inc Earnings Release
Q2 2024 Moderna Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 19263 18471 803.395 60.209 135.068
Revenue 19263 18471 803.395 60.209 135.068
Total Operating Expense 9843 5175 1566.54 605.929 548.334
Selling/General/Admin. Expenses, Total 1132 567 188.267 109.62 94.252
Research & Development 3295 1991 1370.34 496.309 454.082
Operating Income 9420 13296 -763.144 -545.72 -413.266
Interest Income (Expense), Net Non-Operating 151 1 16.125 32.241 23.958
Net Income Before Taxes 9575 13285 -744.513 -514.716 -384.408
Net Income After Taxes 8362 12202 -747.064 -514.021 -384.734
Net Income Before Extra. Items 8362 12202 -747.064 -514.021 -384.734
Net Income 8362 12202 -747.064 -514.021 -384.734
Total Adjustments to Net Income 0 0 -17.123
Income Available to Common Excl. Extra. Items 8362 12202 -747.064 -514.021 -401.857
Income Available to Common Incl. Extra. Items 8362 12202 -747.064 -514.021 -401.857
Diluted Net Income 8362 12202 -747.064 -514.021 -401.857
Diluted Weighted Average Shares 416 431 381.333 330.802 328.799
Diluted EPS Excluding Extraordinary Items 20.101 28.3109 -1.95909 -1.55386 -1.2222
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS 20.101 28.3109 -1.95909 -1.55386 -1.2222
Other, Net 4 -12 2.506 -1.237 4.9
Cost of Revenue, Total 5416 2617 7.933
Gross Profit 13847 15854 795.462
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 344 1862 5084 3364 4749
Revenue 344 1862 5084 3364 4749
Cost of Revenue, Total 731 792 1918 1100 1381
Gross Profit -387 1070 3166 2264 3368
Total Operating Expense 2211 2228 3504 2198 2302
Selling/General/Admin. Expenses, Total 332 305 375 278 211
Research & Development 1148 1131 1211 820 710
Operating Income -1867 -366 1580 1166 2447
Interest Income (Expense), Net Non-Operating 113 65 75 46 27
Other, Net 5 -4 0 5 0
Net Income Before Taxes -1749 -305 1655 1217 2474
Net Income After Taxes -1380 79 1465 1043 2197
Net Income Before Extra. Items -1380 79 1465 1043 2197
Net Income -1380 79 1465 1043 2197
Income Available to Common Excl. Extra. Items -1380 79 1465 1043 2197
Income Available to Common Incl. Extra. Items -1380 79 1465 1043 2197
Diluted Net Income -1380 79 1465 1043 2197
Diluted Weighted Average Shares 381 405 407 412 419
Diluted EPS Excluding Extraordinary Items -3.62205 0.19506 3.59951 2.53155 5.24344
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -3.62205 0.19506 3.59951 2.53155 5.24344
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 13431 16071 6297.88 1128.8 1563.01
Cash and Short Term Investments 9902 10727 4607.61 1103 1521.43
Cash & Equivalents 3205 6848 2623.85 235.876 658.364
Short Term Investments 6697 3879 1983.76 867.124 863.063
Total Receivables, Net 1664 3296 1410.53 16.297 30.583
Accounts Receivable - Trade, Net 1385 3175 1390.56 5.369 12.585
Prepaid Expenses 851 531 232.185 8.475 10.401
Other Current Assets, Total 65 76 1.032 1.032 0.595
Total Assets 25858 24669 7336.75 1589.42 1962.15
Property/Plant/Equipment, Total - Net 2139 1383 387.09 287.909 211.977
Property/Plant/Equipment, Total - Gross 2797 1735 506.751 382.493 276.433
Accumulated Depreciation, Total -658 -352 -119.661 -94.584 -64.456
Long Term Investments 8318 6843 638.848 159.987 172.99
Other Long Term Assets, Total 1970 372 12.933 12.722 14.176
Total Current Liabilities 4923 9128 4388.81 143.115 222.803
Accounts Payable 487 302 18.359 7.09 31.21
Accrued Expenses 2136 1518 475.563 71.236 79.073
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 2139 7143 3870.56 64.789 112.52
Total Liabilities 6735 10524 4775.38 414.612 431.908
Total Long Term Debt 912 599 109.874 38.689 33.489
Capital Lease Obligations 912 599 109.874 38.689 33.489
Other Liabilities, Total 900 797 276.693 232.808 175.616
Total Equity 19123 14145 2561.38 1174.81 1530.24
Preferred Stock - Non Redeemable, Net
Common Stock 0.0385 0 0.04 0.034 0.033
Additional Paid-In Capital 1173 4211 4801.85 2669.43 2538.16
Retained Earnings (Accumulated Deficit) 18320 9958 -2243.52 -1496.45 -1006.63
Other Equity, Total -8.0385 -24
Total Liabilities & Shareholders’ Equity 25858 24669 7336.75 1589.42 1962.15
Total Common Shares Outstanding 385 403 398.788 336.537 328.799
Redeemable Preferred Stock 0 0 0 0 0
Unrealized Gain (Loss) -362 3.004 1.804 -1.32
Total Inventory 949 1441 46.527
Current Port. of LT Debt/Capital Leases 161 165 24.328
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 10799 10599 12122 13431 14297
Cash and Short Term Investments 7573 8459 8923 9902 8348
Cash & Equivalents 2932 3801 3441 3205 3027
Short Term Investments 4641 4658 5482 6697 5321
Total Receivables, Net 2146 688 1521 1628 2821
Accounts Receivable - Trade, Net 1866 232 1113 1385 2695
Total Inventory 487 715 732 949 2077
Prepaid Expenses 497 684 882 887 889
Total Assets 19450 21884 24125 25858 26056
Property/Plant/Equipment, Total - Net 2717 2410 2135 2139 2132
Property/Plant/Equipment, Total - Gross 3789 3236 2871 2797 2712
Accumulated Depreciation, Total -1072 -826 -736 -658 -580
Long Term Investments 5359 6224 7525 8318 8655
Other Long Term Assets, Total 478 2553 2243 1970 972
Total Current Liabilities 4385 3123 3499 4923 6807
Accounts Payable 494 310 389 487 330
Accrued Expenses 2257 1524 1641 2136 1892
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 150 187 153 161 224
Other Current Liabilities, Total 1484 1102 1316 2139 4361
Total Liabilities 5995 4935 5262 6735 8064
Total Long Term Debt 575 843 831 912 922
Capital Lease Obligations 575 843 831 912 922
Other Liabilities, Total 1035 969 932 900 335
Total Equity 13455 16949 18863 19123 17992
Redeemable Preferred Stock 0 0 0 0
Common Stock 0.0381 0.0381 0.0384 0.0385 0.0387
Additional Paid-In Capital 277 193 731 1173 1488
Retained Earnings (Accumulated Deficit) 13389 17019 18399 18320 16855
Unrealized Gain (Loss) -211 -263 -362 -362 -406
Other Equity, Total -0.0381 -0.0381 94.9616 -8.0385 54.9613
Total Liabilities & Shareholders’ Equity 19450 21884 24125 25858 26056
Total Common Shares Outstanding 381 381 384 385 387
Other Current Assets, Total 96 53 64 65 162
Goodwill, Net 52 52 52
Intangibles, Net 45 46 48
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 8362 12202 -747.064 -514.021 -384.734
Cash From Operating Activities 4981 13620 2026.97 -458.968 -330.865
Cash From Operating Activities 348 232 31.251 31.021 24.862
Deferred Taxes -559 -318
Non-Cash Items 285 196 165.73 77.696 71.59
Cash Taxes Paid 2729 480 0.572 0.416 0.294
Changes in Working Capital -3455 1308 2577.05 -53.664 -42.583
Cash From Investing Activities -5176 -8523 -1671.93 -14.945 -373.094
Capital Expenditures -400 -284 -67.448 -31.554 -105.766
Other Investing Cash Flow Items, Total -4776 -8239 -1604.48 16.609 -267.328
Cash From Financing Activities -3448 -873 2033.19 51.121 1226.84
Financing Cash Flow Items 0 0.971 11.635
Issuance (Retirement) of Stock, Net -3264 -733 2039.41 50.15 1217.38
Issuance (Retirement) of Debt, Net -184 -140 -6.215 0 -2.175
Net Change in Cash -3643 4224 2388.24 -422.792 522.883
Cash Interest Paid 25 14 8.528
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 79 8362 6897 5854 3657
Cash From Operating Activities -1225 4981 3319 3067 2763
Cash From Operating Activities 78 348 268 155 79
Deferred Taxes -310 -559 -473 -376 -146
Non-Cash Items 80 285 235 138 62
Changes in Working Capital -1152 -3455 -3608 -2704 -889
Cash From Investing Activities 2011 -5176 -4128 -5073 -3921
Capital Expenditures -113 -400 -308 -219 -132
Other Investing Cash Flow Items, Total 2124 -4776 -3820 -4854 -3789
Cash From Financing Activities -542 -3448 -3010 -1969 -642
Issuance (Retirement) of Stock, Net -517 -3264 -2887 -1892 -611
Issuance (Retirement) of Debt, Net -25 -184 -123 -77 -31
Net Change in Cash 244 -3643 -3819 -3975 -1800

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Moderna, Inc. Company profile

Get all the information you need on the Moderna stock price today with Capital.com’s comprehensive chart.

Moderna (MRNA) is a North American clinical-stage biotechnology company. Headquartered in Cambridge, Massachusetts, it specialises in drug discovery and development, as well as vaccine technologies based on messenger RNA (mRNA). The company is working on therapeutics and vaccines for infectious, autoimmune, immuno-oncology and cardiovascular diseases.

Moderna has a number of strategic partnerships with industry-leading names, such as Vertex Pharmaceuticals (VRTX), AstraZeneca (AZN) and Merck & Co (MRK). In 2020, it also worked with Lonza Group (LONN) and Catalent (CTLT) to manufacture its Covid-19 vaccine candidate mRNA-1273. At the end of 2020, the company had 12 programmes in clinical trials and a total of 23 development candidates.

Moderna shares are listed on the Nasdaq Stock Market under the ticker symbol MRNA. The company is a constituent of the NASDAQ-100 Index.

Stay up-to-date with the latest market news and watch the Moderna share price live at Capital.com.

The company was founded in 2010 as Moderna Therapeutics, with the goal of commercialising the research of stem-cell biologist Derrick Rossi. Apart from Rossi, Moderna’s co-founders were Noubar Afeyan, Robert Langer and Kenneth Chien. In August 2018, the company’s name was changed to Moderna.

In November 2020, Moderna’s Covid-19 vaccine candidate, mRNA-1273, showed preliminary evidence of 94.1 per cent efficacy in preventing the disease in a Phase 3 trial. The results led to its submission for emergency use authorisation in the US, Canada and Europe.

In late November, the EU made a deal with Moderna for up to 160 million doses of its vaccine. In December, the US government exercised its option to buy an additional 100 million doses of Moderna’s mRNA-1273, bringing the confirmed order commitment to 200 million doses.

With Capital.com’s Moderna share price chart, you can not only quickly view the current MRNA stock quote, but also trace the company’s share value in historic terms.

Moderna’s long-awaited initial public offering (IPO) happened in December 2018, with the firm selling 26.3 million shares priced at $23 each. At the time, it was the biggest biotech IPO ever. Moderna raised over $600m, valuing the company at $7.5bn (£5.6bn, €6.2bn).

In 2020, MRNA stock has been one of the US market’s best performers. This was due to rising investor enthusiasm over the company’s promising Covid-19 vaccine candidate. After opening the year at $19.57, the MRNA share price was on a hike, peaking at $94.85 in mid July. Within a month, it had dropped to $54.23, but then the stock gained another upside momentum, with its price surging past $100 on November 16. On December 8, the stock closed the trading day at $169.86, representing a year-to-date gain of nearly 770 per cent.

You can go long or short on the company’s shares and trace all the latest ups and downs of the Moderna Inc. stock price using Capital.com’s proprietary trading platform.

Industry: Biotechnology & Medical Research (NEC)

200 Technology Sq
CAMBRIDGE
MASSACHUSETTS 02139-3578
US

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

ETH/USD

3,094.61 Price
+0.630% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

BTC/USD

64,728.10 Price
+1.710% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

XRP/USD

0.50 Price
-0.710% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Gold

2,381.44 Price
+0.140% 1D Chg, %
Long position overnight fee -0.0190%
Short position overnight fee 0.0108%
Overnight fee time 21:00 (UTC)
Spread 0.40

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading